about
Nuclear myosin VI enhances RNA polymerase II-dependent transcriptionThe rest repression of the neurosecretory phenotype is negatively modulated by BHC80, a protein of the BRAF/HDAC complexPoised transcription factories prime silent uPA gene prior to activation.Gene positioning.Induction of HoxB transcription by retinoic acid requires actin polymerization.Methylation of RNA polymerase II non-consensus Lysine residues marks early transcription in mammalian cells.Arx is a direct target of Dlx2 and thereby contributes to the tangential migration of GABAergic interneurons.FANTOM5 CAGE profiles of human and mouse samplesDown syndrome fibroblasts and mouse Prep1-overexpressing cells display increased sensitivity to genotoxic stress.Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells.p160 Myb-binding protein interacts with Prep1 and inhibits its transcriptional activity.Prep1 directly regulates the intrinsic apoptotic pathway by controlling Bcl-XL levels.Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells.Hierarchical folding and reorganization of chromosomes are linked to transcriptional changes in cellular differentiation.Widespread activation of antisense transcription of the host genome during herpes simplex virus 1 infection.RNA polymerase II primes Polycomb-repressed developmental genes throughout terminal neuronal differentiation.3D chromatin regulation of Sonic hedgehog in the limb buds.A Transcription-dependent Micrococcal Nuclease-resistant Fragment of the Urokinase-type Plasminogen Activator Promoter Interacts with the Enhancer
P50
Q24301373-37878EDA-4635-45CB-BDCC-4E698EFB3973Q28582790-766E17EF-D866-4AD9-87FF-A57E0E1D2511Q33522209-D8B14AB1-02B9-4EBF-ADCE-F86585413CC7Q33849394-46C2CDCC-AF10-49F3-A06D-B4571BE56F6FQ34983598-55F8A3E8-FB92-41AD-AC40-03369F2142A0Q36594202-9A32ED4D-EBF6-4330-80E5-63137927CC24Q37352456-A173F02C-6FAC-425B-9BDC-5311FD0F1087Q38604042-2CB82CBF-AE55-4732-B284-103010D21B2DQ41167097-D111655A-C8BC-4D19-8985-691B168C66A9Q41173167-8AD3451D-3246-4529-8D27-9AE9E5E4C671Q41440879-CBF71050-2DB8-4F0C-AEB6-08BE8DCFE5AFQ41847897-81600F89-1DAA-487A-9579-8C96E2AA9368Q42446956-CDFCCBF1-96E9-43F8-AB43-E8E01F5085C6Q42526967-6D7AA584-F39A-4012-9265-7BC626EB9A05Q43101354-F2CFB4D4-D37E-425D-80D6-A65A43954854Q45325452-35BBEB95-F143-46C5-8605-88A3BF831918Q46594026-D58038FC-7C3A-4FC4-914A-2DBBCDE3D55EQ51942214-FF9A15DE-97B1-41CF-AD0C-FBADD7F045A8Q60609623-C3A37F3F-1622-48D7-BC1B-1796664B20F4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
C Ferrai
@ast
C Ferrai
@en
C Ferrai
@es
C Ferrai
@nl
C Ferrai
@sl
type
label
C Ferrai
@ast
C Ferrai
@en
C Ferrai
@es
C Ferrai
@nl
C Ferrai
@sl
prefLabel
C Ferrai
@ast
C Ferrai
@en
C Ferrai
@es
C Ferrai
@nl
C Ferrai
@sl
P106
P31
P496
0000-0002-8088-2757